Finally, skewing of SARS-CoV-2 SP IgG antibody responses towards IgG3 antibody production in patients with severe COVID-19 (51, 53) might also adversely affect immune responses against SARS-CoV-2 by mechanisms other than myeloid cell activation. This evidence concerns the gene IGHG3 and COVID-19.